Here’s this morning’s Livewire Markets posting – visit www.livewiremarkets.com. continue reading Dead in the womb: New studies reveal Zika’s real threat Watch By Kenya Sinclair (CALIFORNIA NETWORK) A new study indicates the Zika virus is worse than INITIALLY Believed for pregnant women and Their unborn children. ‘I’ve been with my bf a little over three years. “Look at Gardasil – that’s a product that sells $US2 billion a year,” says Chick. Herpes on legs is caused by the herpes simplex virus. How is Admedus’s financial health and their level of debt? Earlier this year Allied increased its stake in Coridon to 44.4% in line with its strategy of focusing on unique drug programs with global implications.
In pre-clinical research, the drug was potent against HSV-1 and HSV-2 isolates and was efficacious in animals, while phase I trials in humans did not raise any safety concerns. Any new patient with suspected genital herpes should have diagnostic testing with virus identification. ”I’ve been knocking on brokers’ doors for four or five years,” says Dr Cumming at Anteo Diagnostic, who points out there has been a slight change in sentiment, with increased analyst coverage of some stocks in the sector. Breakthrough treatment for spiritualsecret64. I feel the same way about disco, Hunter S. In women, the lesions may be visible outside the vagina, but they commonly occur inside the vagina where they can cause discomfort or vaginal discharge and may not be seen except during a doctor’s examination. Cold sores are contagious and are passed to others through direct contact or contact with body fluid.
Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. In the US about 79 million people are currently infected with HPV and each year another 14 million people are infected. These 3 biotechs are speeding ahead to develop a vaccine for herpes. Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus For more information, please contact: Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100 Media: Shevaun Cooper | PR Manager | Admedus Limited Tel: +61 (0) 417 985 599 | Email: firstname.lastname@example.org Media Europe FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000 email@example.com US Investor Rx Communications Group, LLC Melody A. Our model only includes CardioCel in CHD and heart valve repair for conservatism. The company has assets from research & development through clinical development as well as sales, marketing and distribution. The company’s overall objective is to utilise its unique optimisation technology to produce prophylactic and/or therapeutic DNA vaccines for a range of infectious diseases and cancers in humans.
The company has also expanded the CardioCel product range with the addition of 2cm X 2cm and 2cm x 8cm sized products. The DTH response is a cell mediated response. While many of the prospects currently in development are being studied for therapeutic use, the ultimate goal for each company’s platform is to create a prophylactic vaccine to ward off the virus in the first place, MedCity News reports. Admedus continues to advances the keenly awaited key Phase II HSV-2 study with the company anticipating interim results in the fourth quarter of 2015. Australian healthcare group Admedus announced to the stock exchange on Thursday the results of the Phase 1 trial of Professor Frazer’s new vaccine to treat the herpes simplex virus HSV2. The US CDC estimates that 1 in 6 people in the USA between the age of 14 and 49 have contracted the infection. The study also demonstrated that 95% of those trial participants met the clinical trial T-cell positive response endpoint, having generated a positive T-cell response to HSV-2 vaccine antigens.
The company is also progressing with its vascular tissue product range and expanding into dura mater, illustrating its ability to develop an entire portfolio of tissue products. The major failure mode of implanted tissue is calcification. Until this new anti-herpes vaccine is FDA approved, the CBCD recommends that infected individuals take Gene-Eden-VIR or Novirin, which are natural herpes remedies with a formula backed by clinical studies that followed FDA guidelines. In addition, the company has also entered into the promising cancer vaccination/immunotherapy sector, providing another driver for sustained profitable growth. Admedus closed its 1:9 fully underwritten rights issue to raise $8.3 million priced at $0.33 on August 29, 2016. Admedus is focused on continued growth of sales across the company and is expecting at least a 50% growth in revenue in the 2017 financial year, along with expanding its near market product portfolio. Professor Frazer, Australian of the Year in 2006, is also working in collaboration with our team to expand his success with Gardasil®, the preventative vaccine for cervical cancer, to develop a therapeutic vaccine for humans that will treat those with infections and cancers caused by Papillomavirus (HPV).